Topadur Pharma AG is developing TOP-M119, a drug candidate with a novel mode of action for treating androgenic alopecia. Pre-clinical studies reported that TOP-M119 demonstrated higher potency, a faster onset of action and improved local tolerability compared with the standard of care. The company is advancing a liquid topical formulation and is also working on intradermal sustained‑release formulations for medical‑cosmetic applications targeting alopecia and skin ageing. Topadur has signed a co‑development, licensing and commercialization agreement for Greater China to accelerate development and patient access. The partnership initially focuses on completing IND studies and clinical phases I and II. The deal includes an upfront CHF 3 million investment and milestone payments totalling CHF 12 million to cover the estimated development costs. Market context in the article notes the global alopecia market was valued at USD 8.8 billion in 2023 and is projected to exceed USD 16 billion by 2030. Topadur develops drug candidates for severe wounds, including diabetic foot ulcer, chronic wounds, scars and keloids. Its lead R&D programs are locally active, highly potent and employ a dual mode of action the company says offers higher than average clinical success chances. The team aims to improve patients' quality of life and address a large unmet medical need—diabetic foot ulcers and chronic wounds drive hospitalizations, amputations, and more than €10 billion in annual costs. Topadur traces its roots to TOPADUR GmbH (formed in 2010) and its leadership combines substantial pharmaceutical development experience across marketed products. Financially, the company closed an oversubscribed CHF2.2 million Series A and also secured CHF1.2 million in CTI and Eurostars grants to advance development. Management says the proceeds and grants will allow them to move development of their unique drug candidates a significant step forward.

Total raised

$6M

Funding rounds

2

Latest round

Equity

Latest activity

Jun 2024